Soleo Health tapped by health system to provide mAb therapy at home
By HME News Staff
Updated 10:20 AM CDT, Tue September 21, 2021
FRISCO, Texas – Soleo Health has been selected by Houston Methodist to provide monoclonal antibody therapy (mAb) to COVID-19 patients in their homes. The hospital system is among the nation’s largest providers of mAb therapy and has a partnership with the U.S. Department of Human Services, supported by KPMG LLP, to expand access to the treatment to underserved and disadvantaged patients in the greater Houston area. “By teaming up with Houston Methodist to help patients receive therapy and stay in their homes, we are helping reduce the chance of increased infections and the spread of COVID-19 in a hospital setting,” said Shahram L. Badrei, Pharm.D, R.Ph, regional business leader at Soleo Health. “Our relationship with Houston Methodist allows Soleo Health to service a vulnerable population and prevent the spread of the virus. Contributing to the public health and safety of the Houston community is truly important to our company, which is also a Texas-based entity. We look forward to being part of the pandemic solution through this exclusive agreement.” Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens such as viruses. If administered within 10 days of onset of COVID-19 symptoms, the one-time therapy is effective in neutralizing the virus and preventing symptoms from worsening. The treatment is administered through intravenous infusion, delivering medication directly into a patient’s bloodstream.
Comments